Stripe and Peptides: What Gets Brands Banned and What to Do Instead

Stripe publishes a restricted businesses list covering pharmaceuticals, drug paraphernalia and research chemicals, which is where peptide sales sit. Brands that process anyway are usually not warned: the normal sequence is a quiet review, paused payouts, an information request, then closure with the balance held for a period. Read the current policy text yourself before acting, because it is revised.

What the terms actually cover

Three separate provisions matter, and operators usually only think about the first one.

The restricted businesses list. It names pharmaceuticals and related categories alongside research chemicals. A peptide catalogue marketed for research use lands inside that territory in practice, whether or not the specific word appears in the list text.

The clause on unsubstantiated health claims. This one catches your copy rather than your product, and it catches brands who believed their category framing protected them.

The misrepresentation provision. This is the one that actually bites. Describing your business inaccurately at onboarding, or changing what you sell afterwards without saying so, is a separate and more serious breach than selling a listed category openly.

None of this is unique to Stripe. PayPal, Square and Shopify Payments all carry equivalent restrictions in their own terms, for the same structural reason: they underwrite in aggregate, so they exclude categories rather than assess merchants.

How brands actually get caught

Almost nobody is reported by a rival. The triggers are mundane and mostly automatic.

• A scan of the website registered to the account, including product pages, page titles and metadata.
• A dispute in which the cardholder describes the product in their own words in the claim.
• A support ticket or refund request that names the compound.
• A billing descriptor that does not match the registered site, prompting a human to look.
• A volume spike, which triggers routine review at thresholds nobody publishes.
• An external footprint, such as a rejected ad on another platform or a review site link pointing at the store.
• A payout destination that does not match the registered entity.

What termination looks like, step by step

1. A review opens, often with no notification at all.
2. Payouts pause while charges keep succeeding. This is the most dangerous phase, because revenue looks healthy while the held balance grows.
3. An information request arrives with a short deadline: business description, product URLs, supplier documents, fulfilment evidence.
4. A decision. For a listed category the outcome is nearly always closure rather than remediation, however good your answers are.
5. Charging is disabled and any recurring arrangements stop.
6. The balance is held. Months is normal, commonly described as around ninety days, and disputes filed during the window are still charged against you.
7. The remainder pays out less disputes, fees and any reserve.
8. Where closure is for cause, a listing on the industry-wide terminated merchant file that other acquirers query. Listings are commonly described as lasting five years. Verify the current programme rules rather than trusting a summary.

The workarounds that fail, and why

Notice the pattern. Every one of these converts a category problem, which ends in a decline, into a conduct problem, which ends in a listing that follows you to the next acquirer.

What to build instead

• Fix the copy first. Removing outcome claims and any usage guidance from product pages improves your odds with every acquirer at once, and costs an afternoon.
• Apply for a specialist high risk merchant account with a clean site and a complete document pack. The approval mechanics are covered in the peptide merchant account guide.
• Stand up crypto as a live secondary rail today. It takes hours, works while underwriting grinds, and gives you somewhere to send buyers on the day a card account stops.
• Use bank transfer for wholesale, where ticket sizes absorb the friction easily.
• Keep restricted revenue away from any aggregator account you hold, even for another line of business, if it shares an entity, an owner or a site.

The full comparison of rails, fees and reserves sits in the guide to payment processors for peptides.

If you are already terminated

1. Stop charging immediately and do not attempt to reopen under a new name. That single decision determines whether this is a setback or a permanent problem.
2. Get the reason in writing, and ask directly whether the closure was for cause and whether you have been listed anywhere.
3. Ask for the balance release date in writing. Silence is not a policy, it is an unanswered question.
4. Keep fighting disputes during the hold. They still reduce what you eventually receive.
5. Preserve everything. Order records, tracking, and every message, for both the disputes and your next application.
6. Export customer data while you still have access, because access usually disappears at closure.
7. Disclose the termination honestly on the next application. A disclosed closure is survivable. A discovered one is not.
8. Fix the underlying cause before reapplying, or you will buy the same outcome at a higher price.

Mistakes to avoid

• Treating silence as approval. Undetected is not permitted, and the balance at closure is usually larger than the fees you saved.
• Continuing to spend through a payout pause. Held revenue cannot buy stock.
• Arguing the policy instead of fixing the site. Nobody at a payment company can grant an exception to a category list.
• Opening a new account with the same bank details. The link is the first thing checked.
• Writing off a held balance. It is your money, there is a release date, and asking in writing is free.
• Telling customers nothing while orders sit unfulfilled. Silence generates the disputes that shrink the balance you are waiting on.

Educational content for brand operators, not legal, financial, or medical advice. BestPeptideBrand.lol runs a transparent paid leaderboard: rankings on the board are ordered by bid amount only and a listing is not an endorsement.